TABLE 1.
Baseline and clinical characteristics
| Parametera | Value |
|---|---|
| No. of patients | 17 |
| No. of female patients (%) | 1 (5.9) |
| Median age (yrs) (range) | 55 (31–74) |
| Median WHO ordinal scale score (range) | 5 (5–5) |
| Median oxygen requirement at admission (L/min) (range) | 4 (1–15) |
| Median no. of days of complaints prior to admission (range) | 9 (4–22) |
| Median time from start of complaints to remdesivir (days) (range) | 10 (4–22) |
| Median time from hospitalization to start of remdesivir (days) (range) | 0 (0–1) |
| Median hospitalization durationb (days) (range) | 4 (1–64) |
| No. of patients with ICU admissionb (%) | 3 (17.6) |
| No. of patients with mortality during hospitalizationb (%) | 1 (5.9) |
| Median body wt (kg) (range) | 92 (65–122) |
| Median BMI (kg/m2) (range) | 30.86 (21.72–41.21) |
| Median body surface area (m2) (range) | 2.11 (1.77–2.52) |
| Median creatinine concn (μmol/L) (range) | 75 (46–573) |
| Median eGFR (CKD-EPI) (mL/min/1.73 m2) (range) | 94 (8–119) |
| Median albumin concn (g/L) (range) | 37 (30–47) |
| Median total bilirubin concn (μmol/L) (range) | 8 (2–18) |
| Median hemoglobin concn (mmol/L) (range) | 8 (6.6–11.1) |
| Median white blood cell count (109/L) (range) | 6.8 (3.4–15.1) |
| Median urea concn (mmol/L) (range) | 4.9 (2.4–17.6) |
| Median CRP concn (mg/L) (range) | 147 (6–346) |
| Median ALT concn (U/L) (median) | 36 (20–150) |
| Median D-dimer concn (mg/L) (range) | 0.37 (0.17–1.45) |
| No. of comorbidities (%) | |
| Cardiovascular disease | 5 (29) |
| Diabetes mellitus | 6 (35) |
| Asthma | 1 (5.9) |
| Malignancy | 1 (5.9) |
a
ICU, intensive care unit.
b
Four patients were transferred to another hospital during COVID-19 treatment due to hospital bed occupancy.